Home Featured Page 192

Featured

Latest

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

Psychedelic Policy Briefing: Week of July 6, 2026

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial...

Albert Labs Files US Provisional Patent Application and Proves Out Consistent...

PT305 – Emma Farrell – Plant Spirits, Entities, and Remembering Lost...

MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Announces Transition of CFO

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Nova Mentis Begins Enrollment in North American Autism Study

Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing...

EDITOR PICKS

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data;...

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

Psychedelic Policy Briefing: Week of July 6, 2026

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial...

Albert Labs Files US Provisional Patent Application and Proves Out Consistent...

PT305 – Emma Farrell – Plant Spirits, Entities, and Remembering Lost...

MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Announces Transition of CFO

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Nova Mentis Begins Enrollment in North American Autism Study

Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing...

EDITOR PICKS

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data;...

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY